- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We’re Reading: Testing COVID-19 Antiviral Pill in Children; Flavored e-Cigarette Loophole; New Kawasaki Disease Guideline
Pfizer will begin phase 2 and 3 trials of its COVID-19 antiviral pill in children 6 years and older; lawmakers respond after e-cigarette companies began using unregulated synthetic nicotine to get around FDA regulation; the American College of Rheumatology released a new guideline on the management of Kawasaki disease.
Pfizer Set to Begin Phase 2, 3 Trials on COVID-19 Antiviral Pill in Younger Children
Pfizer announced it will begin phase 2 and 3 testing of its COVID-19 antiviral pill, Paxlovid, in children 6 years and older, Politico reported. The FDA approved Paxlovid for children 12 years and older at high risk for COVID-19 in December 2021. These trials will focus on a younger age group who have tested positive for COVID-19, are not hospitalized, and are at risk of developing severe COVID-19. Based on the findings in these trials, Pfizer plans to develop a Paxlovid dose for children younger than 6 years and enroll children in this age group in the ongoing trial.
Lawmakers Seek End to Loophole in FDA Regulation Exploited by e-Cigarette Makers
Despite an FDA crackdown on flavored e-cigarettes back in 2020, sales have “soared” in 2022 due to a loophole. The FDA had regulated e-cigarettes containing tobacco plant-derived nicotine. To get around this, some companies such as Puff Bar have switched to using an unregulated synthetic nicotine. On Tuesday, US lawmakers proposed to adjust the language in the Congressional omnibus budget bill to give the FDA authority to regulate synthetic nicotine as well, although it is unclear if this issue will be included in the final bill, The New York Times reported.
ACR Releases New Kawasaki Disease Guideline
The American College of Rheumatology (ACR) released a new guideline regarding the management of Kawasaki disease. This guideline, released in partnership with the Vasculitis Foundation, focuses on Kawasaki disease diagnosis issues, treatment in high-risk patients, and disease management in convalescent or recovering patients. Eleven treatment recommendations are included in the new ACR guideline, including 2 that differ from the current standards: higher-risk patients should receive short courses of corticosteroids at time of first diagnosis, and physicians can decide whether to use high- or low-dose aspirin for therapy.
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Workers Facing Greater Economic Hardship More Likely to Report Poor Health
June 2nd 2025US workers facing high economic hardship, especially those in lower-wage occupations, were significantly more likely to report fair or poor health, underscoring persistent disparities in worker well-being.
Read More
